基于RIP1/RIP3/NLRP3信号通路探讨祛瘀生新方治疗溃疡性结肠炎小鼠的作用机制

吴闯; 韩昌鹏; 汪庆明; 张海岩; 黄烃; 茅闻婧; 杨巍

doi:10.3969/j.issn.1671-038X.2021.02.08

基于RIP1/RIP3/NLRP3信号通路探讨祛瘀生新方治疗溃疡性结肠炎小鼠的作用机制

- 1 上海市宝山区中西医结合医院肛肠科(上海, 201999);
- 2 上海中医药大学附属岳阳中西医结合医院肛肠科
基金项目:
国家自然科学基金(No:81704078)

国家自然科学基金(No:81874468)

上海市中医药三年行动计划项目[No:ZY(2018-2020)-CCCX-2004-09]

详细信息

通讯作者: 杨巍,E-mail:13917198396@136.com

中图分类号: R574.62

收稿日期: 2020-08-11

Mechanism of Quyushengxin decoction for treating ulcerative colitis in mice: the role of RIP1/RIP3/NLRP3 pathway

- 1 Department of Anorectal, Shanghai Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 201999, China;
- 2 Department of Anorectal, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

More Information

Corresponding author: YANG Wei, E-mail: 13917198396@136.com

Received Date: 11 August 2020

摘要

摘要: 目的:研究祛瘀生新方对溃疡性结肠炎(UC)小鼠的治疗效果以及对RIP1/RIP3/NLRP3信号通路的调节作用。方法:将36只小鼠随机分为实验组(祛瘀生新组)、模型组、阳性对照组(美莎拉嗪组)、空白组、中药拆方1组(生新组)、中药拆方2组(祛瘀组),6只/组,采用3.5%葡聚糖硫酸钠盐(DSS)溶液自由饮水法制备UC小鼠模型,7 d后进行相应药物干预,每天称重小鼠,评估DAI积分,灌胃7 d后处死小鼠取结肠组织并测量长度。对结肠进行苏木精-伊红染色观察各组小鼠结肠组织形态变化及病理学评分情况。采用RT-qPCR、ELISA检测并比较各组小鼠结肠中RIP1、RIP3、NLRP3、IL-1βmRNA及其蛋白表达水平。结果:干预前非空白组小鼠体重差异无统计学意义(P>0.05);祛瘀生新组、模型组、美莎拉嗪组、生新组、祛瘀组小鼠结肠长度明显短于空白组(P<0.05);中药组、美莎拉嗪组、空白组与祛瘀组DAI评分低于模型组(P<0.05);各组病理评分均低于模型组(P<0.05);各组RIP1、RIP3、IL-1βmRNA明显低于模型组(P<0.05);其中祛瘀组NLRP3 mRNA与模型组比较,差异无统计学意义(P>0.05);祛瘀生新组与美莎拉嗪组RIP1、RIP3、NLRP3、IL-1βmRNA水平比较,差异无统计学意义(P>0.05);祛瘀组IL-1βmRNA低于生新组(P<0.05);生新组NLRP3 mRNA低于祛瘀组(P<0.05)。各组RIP1、NLRP3、IL-1β与模型组比较,差异有统计学意义(P<0.01);而祛瘀生新组RIP3、IL-1β与空白组比较,差异无统计学意义(P>0.05)。结论:祛瘀生新方对UC有一定的治疗作用,其中祛瘀中药和生新中药需要配合使用方能达到更好效果,可能是通过RIP1/RIP3/NLRP3通路抑制RIP1、RIP3、NLRP3、IL-1β的表达控制炎症而起作用。
- 溃疡性结肠炎 /
- 祛瘀生新方 /
- RIP1/RIP3/NLRP3信号通路
Abstract: Objective: To study the effect of Quyu Shengxin(QYSX) decoction on UC mice and the regulation of RIP1/RIP3/NLRP3 pathway.Methods: Thirty-six mice were randomly divided into experimental group(QYSX group), model group, positive control group(Mesalazine group), blank group, TCM disassembled Formula 1 group(QY group), and TCM disassembled formula 2 group(SX formula group), 6 mice per group. UC mice model was prepared by 3.5% DSS drinking water method. Corresponding drug treatment was applied to mice on the 7^thday. Implementing daily mice weighting and regular DAI scores evaluation. The colon tissue was dissected and the length was measured, the morphological changes was observed with HE staining and pathological scores of each group was rated. The mRNA and protein expression level of RIP1, RIP3, NLRP3, IL-1β were tested by RT-qPCR and ELISA.Results: Weight of non-blank group appeared no significant difference before treatment(P<0.05). The colon length of QYSX group, Model group, Mesalazine group, SX group, QY group was clearly shorter than the blank group(P<0.05). The DAI scores of QYSX group, MSLZ group, blank group and SX group was significantly lower than model group(P<0.05). Pathological scores,RIP1,RIP3,IL-1βmRNA of other groups(except Model group) was significantly lower than Model group(P<0.05). NLRP3 mRNA of QY group showed consistent results compared to model group(P>0.05). There was no differentiated results showed on RIP1,RIP3,NLRP3,IL-1βmRNA between QYSX group and Mesalazine group(P>0.05). IL-1βmRNA of QY group showed lower than SX group(P>0.05). NLRP3 mRNA of SX group showed lower than QY group(P>0.05). RIP1,NLRP3,IL-1βof other groups showed significantly differences with model group(P<0.01). However, RIP3、IL-1βof QYSX group showed no major difference with Blank group(P>0.05).Conclusion: QYSX formula has certain therapeutic effect on UC. Better therapeutic effect showed by using combination of QYSX Decoction and QuyuShengxin decoction, which could be resulted by inhibiting the expression of RIP1, RIP3, NLRP3 and IL-1β through RIP1/RIP3/NLRP3 pathway to control inflammation.
- ulcerative colitis /
- Quyu Shengxin decoction /
- RIP1/RIP3/NLRP3 pathway

HTML全文

参考文献(29)

[1]	Eisenstein M.Ulcerative colitis:towards remission[J].Nature,2018,563(7730):S33.
[2]	Ng WK,Wong SH,Ng SC.Changing epidemiological trends of inflammatory bowel disease in Asia[J].Intest Res,2016,14(2):111-119.
[3]	Zhen Y,Zhang H.NLRP3 Inflammasome and Inflammatory Bowel Disease[J].Front Immunol,2019,10:276.
[4]	Ranson N,Veldhuis M,Mitchell B,et al.NLRP3-Dependent and-Independent Processing of Interleukin(IL)-1β in Active Ulcerative Colitis[J].Int J Mol Sci,2018,20(1):57.
[5]	吴闯,王芳.从瘀虚论治溃疡性结肠炎[J].山东中医杂志,2012,31(10):731-732.
[6]	Harris PA,Berger SB,Jeong JU,et al.Discovery of a First-in-Class Receptor Interacting Protein 1(RIP1) Kinase Specific Clinical Candidate(GSK2982772) for the Treatment of Inflammatory Diseases[J].J Med Chem,2017,60(4):1247-1261.
[7]	Wu T,Dai Y,Xue L,et al.Expression of receptor interacting protein 3 and mixed lineage kinase domain-like protein-key proteins in necroptosis is upregulated in ulcerative colitis[J].Ann Palliat Med,2019,8(4):483-489.
[8]	Wirtz S,Popp V,Kindermann M,et al.Chemically induced mouse models of acute and chronic intestinal inflammation[J].Nat Protoc,2017,12(7):1295-1309.
[9]	Ungaro R,Mehandru S,Allen PB,et al.Ulcerative colitis[J].Lancet,2017,389(10080):1756-1770.
[10]	Greuter T,Vavricka SR.Extraintestinal manifestations in inflammatory bowel disease-epidemiology,genetics,and pathogenesis[J].Expert Rev Gastroenterol Hepatol,2019,13(4):307-317.
[11]	Yan P,Wang Y,Meng X,et al.Whole Exome Sequencing of Ulcerative Colitis-associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients[J].Inflamm Bowel Dis,2019,25(8):1293-1301.
[12]	Roberts-Thomson IC,Bryant RV,Costello SP.Uncovering the cause of ulcerative colitis[J].JGH Open,2019,3(4):274-276.
[13]	Ungaro R,Mehandru S,Allen PB,et al.Ulcerative colitis[J].Lancet,2017,389(10080):1756-1770.
[14]	Bohl JL,Sobba K.Indications and Options for Surgery in Ulcerative Colitis[J].Surg Clin North Am,2015,95(6):1211-1132.
[15]	吴佳,李胜吾,张镭潇,等.从《黄帝内经》辨析溃疡性结肠炎的病因病机及预后[J].山东中医杂志,2012,31(5):309-310.
[16]	杨美霞,郑红斌,张心平,等.《黄帝内经》肠痹理论在溃疡性结肠炎诊治中的应用[J].浙江中医杂志,2020,55(3):167-168.
[17]	叶天士.临证指南医案[M].北京:人民卫生出版社,2006:175-175.
[18]	吴闯,夏宇虹,王芳,等.溃结Ⅱ号方治疗溃疡性结肠炎33例[J].中国中西医结合外科杂志,2014,(4):404-406.
[19]	Newton K,Manning G.Necroptosis and Inflammation[J].Annu Rev Biochem,2016,85:743-763.
[20]	Newton K.RIPK1 and RIPK3:critical regulators of inflammation and cell death[J].Trends Cell Biol,2015,25(6):347-353.
[21]	Negroni A,Colantoni E,Pierdomenico M,et al.RIP3 AND pMLKL promote necroptosis-induced inflammation and alter membrane permeability in intestinal epithelial cells[J].Dig Liver Dis,2017,49(11):1201-1210.
[22]	Degterev A,Ofengeim D,Yuan J.Targeting RIPK1 for the treatment of human diseases[J].Proc Natl Acad Sci U S A,2019,116(20):9714-9722.
[23]	Guo Y,Wu X,Wu Q,et al.Dihydrotanshinone I,a natural product,ameliorates DSS-induced experimental ulcerative colitis in mice[J].Toxicol Appl Pharmacol,2018,344:35-45.
[24]	Lee SH,Kwon JY,Moon J,et al.Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients[J].Immune Netw,2020,20(2):e16.
[25]	夏宏光,吴劼,段树民,等.新型RIP1/RIP3双靶点抑制剂及其在一药多靶疾病治疗中的用途:CN110759895A[P].2020-02-07.
[26]	Lee SH,Kwon JY,Moon J,et al.Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients[J].Immune Netw,2020,20(2):e16.
[27]	Wang X,Jiang W,Yan Y,et al.RNA viruses promote activation of the NLRP3 inflammasome through a RIP1-RIP3-DRP1 signaling pathway[J].Nat Immunol,2014,15(12):1126-1133.
[28]	Li Y,Führer M,Bahrami E,et al.Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases[J].Proc Natl Acad Sci USA,2019,116(3):970-975.
[29]	Liu ZY,Zheng M,Li YM,et al.RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression[J].Theranostics,2019,9(12):3659-3673.